Cloudbreak Therapeutics, LLC

Patent Applications and Registrations

Patent applications and USPTO patent grants for Cloudbreak Therapeutics, LLC.The latest application filed is for "emulsion formulations of multikinase inhibitors".

Company Profile

11.18.14

Cloudbreak Therapeutics, LLC - Irvine CA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Emulsion Formulations Of Multikinase Inhibitors App 20220040103 - Ni; Jinsong ; et al.	2022-02-10
Emulsion Formulations Of Multikinase Inhibitors App 20210315815 - Ni; Jinsong ; et al.	2021-10-14
Compositions And Methods For Treating Pterygium Recurrence App 20210308042 - Ni; Jinsong	2021-10-07
A Composition For Treating Ocular Hyperemia And A Method For Treating Ocular Hyperemia With The Same App 20210228574 - WHITCUP; Scott ; et al.	2021-07-29
Compositions and methods for treating eye diseases Grant 11,007,214 - Ni , et al. May 18, 2	2021-05-18
Compositions and methods for treating pterygium recurrence Grant 10,980,741 - Ni April 20, 2	2021-04-20
Compositions And Methods For Treating Eye Diseases App 20210093657 - NI; Jinsong ; et al.	2021-04-01
Compositions For Treating Meibomian Gland Dysfunction App 20210000860 - NI; Jinsong ; et al.	2021-01-07
Compositions And Methods Of Using Nintedanib For Treating Ocular Diseases With Abnormal Neovascularization App 20200323844 - Ni; Jinsong ; et al.	2020-10-15
Compositions and methods for treating meibomian gland dysfunction Grant 10,744,153 - Ni , et al. A	2020-08-18
Compositions and methods of using nintedanib for improving glaucoma surgery success Grant 10,688,092 - Ni , et al.	2020-06-23
Compositions And Methods Of Using Nintedanib For Improving Glaucoma Surgery Success App 20190290643 - Ni; Jinsong ; et al.	2019-09-26
Compositions and methods of using nintedanib for improving glaucoma surgery success Grant 10,335,408 - Ni , et al.	2019-07-02
Compositions And Methods For Treating Pterygium Recurrence App 20190110984 - Ni; Jinsong	2019-04-18
Compositions And Methods Of Using Nintedanib For Improving Glaucoma Surgery Success App 20190015409 - Ni; Jinsong ; et al.	2019-01-17
Compositions and methods for treating pterygium Grant 10,149,820 - Ni Dec	2018-12-11
Compositions and methods for treating hyperemia Grant 10,149,819 - Ni Dec	2018-12-11
Compositions And Methods For Treating Pterygium App 20180271781 - Ni; Jinsong	2018-09-27
Compositions And Methods For Treating Hyperemia App 20180271780 - Ni; Jinsong	2018-09-27
Compositions and methods for treating pterygium Grant 9,987,223 - Ni June 5, 2	2018-06-05
Compositions and methods for treating pterygium Grant 9,980,901 - Ni May 29, 2	2018-05-29
Compositions And Methods For Treating Pterygium App 20170209368 - Ni; Jinsong	2017-07-27
Compositions And Methods For Treating Pterygium App 20170172915 - Ni; Jinsong	2017-06-22

Company Registrations

NCAGE Code	7NCC1	CLOUDBREAK THERAPEUTICS LLC
CAGE Code	7NCC1	CLOUDBREAK THERAPEUTICS LLC
S.A.M. Registration	7NCC1 [66097357]	CLOUDBREAK THERAPEUTICS LLC

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.